Sinopharm Group Co. Ltd (X2S) — Cash Flow-to-Debt Ratio
Sinopharm Group Co. Ltd (X2S) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2023, meaning its operating cash flow of €-2.63 Billion could theoretically repay 0% of its total liabilities (€304.58 Billion) in one year. See how much free cash does Sinopharm Group Co. Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinopharm Group Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Sinopharm Group Co. Ltd across 13 annual periods. Also explore net asset momentum of Sinopharm Group Co. Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for Sinopharm Group Co. Ltd. For market capitalisation and broader financial context, see X2S stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | €14.14 Billion | €256.20 Billion | ▲ +27.2% |
| 2024 | 0.04x | €11.55 Billion | €266.14 Billion | ▼ -33.5% |
| 2023 | 0.07x | €17.17 Billion | €263.08 Billion | ▼ -20.7% |
| 2022 | 0.08x | €20.96 Billion | €254.71 Billion | ▲ +108.5% |
| 2021 | 0.04x | €9.31 Billion | €235.76 Billion | ▼ -21.7% |
| 2020 | 0.05x | €11.15 Billion | €221.29 Billion | ▼ -48.2% |
| 2019 | 0.10x | €18.78 Billion | €192.95 Billion | ▲ +346.1% |
| 2018 | 0.02x | €3.65 Billion | €167.50 Billion | ▼ -19.6% |
| 2017 | 0.03x | €3.21 Billion | €118.27 Billion | ▼ -66.8% |
| 2016 | 0.08x | €9.26 Billion | €113.18 Billion | ▼ -39.9% |
| 2015 | 0.14x | €13.41 Billion | €98.55 Billion | ▲ +126.1% |
| 2014 | 0.06x | €5.56 Billion | €92.37 Billion | ▼ -6.4% |
| 2013 | 0.06x | €4.94 Billion | €76.84 Billion | — |